 Since 1999, there's been more than half a million people that actually died from some sort of opioid overdose. There's a wide availability of naloxone, which is the antidote to be able to essentially recover them in the event of an overdose. But a lot of times, these patients who overdose are found alone are incapacitated to be able to inject this lifesaving drug themselves. We're trying to come up with a closed-loop solution that can automatically deliver a antidote. So the idea is to be able to measure the rate of respiration using some sort of wearable sensor, and then be able to use that as some sort of a threshold to be able to trigger release of the antidote that's going to be implanted underneath the skin. So you will have a antidote carrying with you just in case you have an accident. And then when the system detects that you're having some sort of respiratory failure, the drug will be released automatically to give you additional time to get medical attention. The activation device is composed of battery microcontroller and the actual induction device. And what microcontroller does is get a signal from the ECG, your heart rate, and then it will turn on the activation device. And this activation device will give alternating magnetic field, which is very fastly rapidly changing magnetic field. And then this magnetic field will induce heat in the metal piece inside the capsule. This capsule, which is kept with a phase changing material, will heat up due to the stainless steel. And then when it reaches the melting temperature, it melts out and the drug component will diffuse out. This approach is unique for opioid overdose because there isn't a automatically injectable drug delivery system. There's a system to make the injection of Naloxone easier for the person who is overdosing, but if they're unresponsive, there's no way for the person to actually inject themselves. Right now we have a proof of concept device to be able to show that we can measure respiration, we can use a signal to activate the triggering of the drug release. We're trying to essentially mitigate any types of risk in case the device fails because this would be a life-saving device and we don't wanna have any kind of failure. So we wanna have a lot of redundancy, wanna make sure that we have a very high confidence that this device will work at a time of need.